Company & Sponsor Intelligence
Axsome Therapeutics, Inc.
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials3
Recruiting1
Completed1
Countries1
Therapeutic footprint
adhdalzheimers
Indexed studies
NCT04947553A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation
alzheimers · United StatesPHASE3
alzheimers · United StatesPHASE3
NCT06736509An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study
alzheimers · United StatesPHASE3
alzheimers · United StatesPHASE3
NCT07717879A Study to Assess the Efficacy and Safety of Solriamfetol in Children With ADHD
adhd · United StatesPHASE3
adhd · United StatesPHASE3
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →